A Theranos investor says the company never disclosed it wasn’t using its own tech

Brian Grossman of PFM Health Sciences tried to conduct detailed due diligence on Theranos, he testified in court.

PFM Health Sciences partner Brian Grossman

PFM Health Sciences partner Brian Grossman leaves the courthouse in San Jose Tuesday.

Photo: Biz Carson / Protocol

PFM Health Sciences partner Brian Grossman had a laundry list of due-diligence questions for the latest investment he was considering.

"How does your accuracy and speed stack up against your traditional tests?"

"What are the limitations of the technology? What tests are not feasible?"

The answers he got back from the company — Theranos — obfuscated the truth, he testified on Tuesday in the ongoing criminal fraud trial of Elizabeth Holmes, the blood-testing startup's co-founder and former CEO.

As he faced repeated questioning by Assistant U.S. Attorney Robert Leach, Grossman said he was never told that Theranos' own analyzers were only being used for a handful of tests. He did not know that modified commercial machines were being used, he said, and he "absolutely" did not know that Theranos' expenses included the cost of the Siemens machines it was using to test patient samples.

Instead, he said he was pitched on a 10-year-old company whose technology had been vetted, validated and used on the battlefield and medevac helicopters "in matters of life and death." In his first meeting with company executives in December 2013, he was told by Holmes and Sunny Balwani, Theranos' then-president who is also facing fraud charges, that it had taken Theranos a decade to get to the point where it could run every test on the menu of its largest competitors. They emphasized that their technology was "better than conventional lab equipment" with lower variability.

Grossman was particularly enamored with the potential Theranos had for replacing an entire laboratory in a box — a move that would have had major implications to the cost structure of health care if you could scale down the square footage and people needed to operate testing. And, importantly to Grossman, it was a technology that had made it beyond the lab and into Walgreens stores, being run on human samples.

"Was that impressive?" Leach asked. "Very," Grossman replied.

So far, much of the testimony from Theranos investors in the drawn-out trial has exposed gaps in due diligence and how FOMO overruled formal process. But Grossman's testimony has been notable for just how much due diligence his firm did and the pushback he had received from Theranos along the way.

"From a bigger-picture perspective, we wanted to understand if there was development technological risk, or if we were investing in a company that was past that proof of concept and the risks were commercial roll-out and business strategy," Grossman said.

When he tried to reach out to companies like Walgreens and United Healthcare, Balwani wouldn't allow him to talk to the companies, Grossman said.

"He said 'No, we are not comfortable with that. It would look badly if investors are asking to speak with the company,'" Grossman said. The PFM investor ended up talking to Channing Robertson, a Stanford professor and former board member, who signed off on the technology as not having serious risks.

Grossman then worked with Balwani to arrange a tour of the manufacturing facility and the lab at Theranos, but faced resistance because the company was concerned he would see unpatented work and it would "compromise their intellectual property." Balwani acquiesced and allowed him to visit after saying he'd move some machines, and when Grossman toured the manufacturing facility and the CLIA lab, he said he only saw miniLabs and not the third-party devices that often ran the tests.

Grossman also tried the Theranos miniLab himself, or at least attempted to.

He went to a Walgreens to have his own blood drawn, only to end up with a venous draw instead of a fingerstick prick. After the results came back past the promised four-hour window, Grossman raised concerns with Balwani, who assured him it was just a problem with a specific test.

An email shown in court revealed that Grossman's test had actually been run on a Siemens Immulite machine and not one of Theranos' proprietary devices, something he didn't know at the time. (A different analyst at PFM did successfully get a fingerprick test, the defense showed in their cross-examination.)

Defense attorney Lance Wade pressed Grossman on the idea that he should have known if his blood was being collected by a venous draw that the lab would've been using a third-party device, but Grossman said he believed the microsample, taken with a venous draw, meant it would still be used on the Theranos proprietary device designed for smaller samples.

"I would be concerned if someone was using a microsample from traditional methods and using that on traditional lab equipment," Grossman replied. "That would be concerning for me."

Wade noted that despite PFM's long list of diligence questions, it never explicitly asked if Theranos did use third-party devices. Grossman conceded his firm didn't pose that question.

Even with the hiccups in the diligence process, Grossman's fund went ahead and invested roughly $96 million because it believed the representations Holmes had made about Theranos' capabilities — without revealing what was really going on in the labs.

Grossman's testimony is expected to continue Wednesday.


Musk’s texts reveal what tech’s most powerful people really want

From Jack Dorsey to Joe Rogan, Musk’s texts are chock-full of überpowerful people, bending a knee to Twitter’s once and (still maybe?) future king.

“Maybe Oprah would be interested in joining the Twitter board if my bid succeeds,” one text reads.

Photo illustration: Patrick Pleul/picture alliance via Getty Images; Protocol

Elon Musk’s text inbox is a rarefied space. It’s a place where tech’s wealthiest casually commit to spending billions of dollars with little more than a thumbs-up emoji and trade tips on how to rewrite the rules for how hundreds of millions of people around the world communicate.

Now, Musk’s ongoing legal battle with Twitter is giving the rest of us a fleeting glimpse into that world. The collection of Musk’s private texts that was made public this week is chock-full of tech power brokers. While the messages are meant to reveal something about Musk’s motivations — and they do — they also say a lot about how things get done and deals get made among some of the most powerful people in the world.

Keep Reading Show less
Issie Lapowsky

Issie Lapowsky ( @issielapowsky) is Protocol's chief correspondent, covering the intersection of technology, politics, and national affairs. She also oversees Protocol's fellowship program. Previously, she was a senior writer at Wired, where she covered the 2016 election and the Facebook beat in its aftermath. Prior to that, Issie worked as a staff writer for Inc. magazine, writing about small business and entrepreneurship. She has also worked as an on-air contributor for CBS News and taught a graduate-level course at New York University's Center for Publishing on how tech giants have affected publishing.

Sponsored Content

Great products are built on strong patents

Experts say robust intellectual property protection is essential to ensure the long-term R&D required to innovate and maintain America's technology leadership.

Every great tech product that you rely on each day, from the smartphone in your pocket to your music streaming service and navigational system in the car, shares one important thing: part of its innovative design is protected by intellectual property (IP) laws.

From 5G to artificial intelligence, IP protection offers a powerful incentive for researchers to create ground-breaking products, and governmental leaders say its protection is an essential part of maintaining US technology leadership. To quote Secretary of Commerce Gina Raimondo: "intellectual property protection is vital for American innovation and entrepreneurship.”

Keep Reading Show less
James Daly
James Daly has a deep knowledge of creating brand voice identity, including understanding various audiences and targeting messaging accordingly. He enjoys commissioning, editing, writing, and business development, particularly in launching new ventures and building passionate audiences. Daly has led teams large and small to multiple awards and quantifiable success through a strategy built on teamwork, passion, fact-checking, intelligence, analytics, and audience growth while meeting budget goals and production deadlines in fast-paced environments. Daly is the Editorial Director of 2030 Media and a contributor at Wired.

Circle’s CEO: This is not the time to ‘go crazy’

Jeremy Allaire is leading the stablecoin powerhouse in a time of heightened regulation.

“It’s a complex environment. So every CEO and every board has to be a little bit cautious, because there’s a lot of uncertainty,” Circle CEO Jeremy Allaire told Protocol at Converge22.

Photo: Circle

Sitting solo on a San Francisco stage, Circle CEO Jeremy Allaire asked tennis superstar Serena Williams what it’s like to face “unrelenting skepticism.”

“What do you do when someone says you can’t do this?” Allaire asked the athlete turned VC, who was beaming into Circle’s Converge22 convention by video.

Keep Reading Show less
Benjamin Pimentel

Benjamin Pimentel ( @benpimentel) covers crypto and fintech from San Francisco. He has reported on many of the biggest tech stories over the past 20 years for the San Francisco Chronicle, Dow Jones MarketWatch and Business Insider, from the dot-com crash, the rise of cloud computing, social networking and AI to the impact of the Great Recession and the COVID crisis on Silicon Valley and beyond. He can be reached at bpimentel@protocol.com or via Google Voice at (925) 307-9342.


Is Salesforce still a growth company? Investors are skeptical

Salesforce is betting that customer data platform Genie and new Slack features can push the company to $50 billion in revenue by 2026. But investors are skeptical about the company’s ability to deliver.

Photo: Marlena Sloss/Bloomberg via Getty Images

Salesforce has long been enterprise tech’s golden child. The company said everything customers wanted to hear and did everything investors wanted to see: It produced robust, consistent growth from groundbreaking products combined with an aggressive M&A strategy and a cherished culture, all operating under the helm of a bombastic, but respected, CEO and team of well-coiffed executives.

Dreamforce is the embodiment of that success. Every year, alongside frustrating San Francisco residents, the over-the-top celebration serves as a battle cry to the enterprise software industry, reminding everyone that Marc Benioff’s mighty fiefdom is poised to expand even deeper into your corporate IT stack.

Keep Reading Show less
Joe Williams

Joe Williams is a writer-at-large at Protocol. He previously covered enterprise software for Protocol, Bloomberg and Business Insider. Joe can be reached at JoeWilliams@Protocol.com. To share information confidentially, he can also be contacted on a non-work device via Signal (+1-309-265-6120) or JPW53189@protonmail.com.


The US and EU are splitting on tech policy. That’s putting the web at risk.

A conversation with Cédric O, the former French minister of state for digital.

“With the difficulty of the U.S. in finding political agreement or political basis to legislate more, we are facing a risk of decoupling in the long term between the EU and the U.S.”

Photo: David Paul Morris/Bloomberg via Getty Images

Cédric O, France’s former minister of state for digital, has been an advocate of Europe’s approach to tech and at the forefront of the continent’s relations with U.S. giants. Protocol caught up with O last week at a conference in New York focusing on social media’s negative effects on society and the possibilities of blockchain-based protocols for alternative networks.

O said watching the U.S. lag in tech policy — even as some states pass their own measures and federal bills gain momentum — has made him worry about the EU and U.S. decoupling. While not as drastic as a disentangling of economic fortunes between the West and China, such a divergence, as O describes it, could still make it functionally impossible for companies to serve users on both sides of the Atlantic with the same product.

Keep Reading Show less
Ben Brody

Ben Brody (@ BenBrodyDC) is a senior reporter at Protocol focusing on how Congress, courts and agencies affect the online world we live in. He formerly covered tech policy and lobbying (including antitrust, Section 230 and privacy) at Bloomberg News, where he previously reported on the influence industry, government ethics and the 2016 presidential election. Before that, Ben covered business news at CNNMoney and AdAge, and all manner of stories in and around New York. He still loves appearing on the New York news radio he grew up with.

Latest Stories